Steven Shane - Science Applications Independent Director
| SAIC Stock | USD 124.20 0.58 0.46% |
Director
Mr. Steven R. Shane serves as Independent Director of the Company. He retired in September 2011 as a partner of Accenture plc, a management consulting, technology and outsourcing services firm, after a 30year career. While at Accenture, Mr. Shane was the Managing Partner of the North America Public Service business for Accenture responsible for Accentures U.S. federal, state and local and Canadian federal and provincial business. He also held several other senior management positions, including those where he led consulting engagements for many of the largest banking institutions in the United States. Following his retirement from Accenture, Mr. Shane joined LHP, LLC, a boutique consulting company, where he provides strategic, organizational and business advice to senior executives in some of the largest U.S. financial services companies. Mr. Shane also is a member of the Board of Directors and chair of the Audit Committee of ZPower, LLC and serves as an Advisory Board Member for MAXIMUS Federal Services. since 2013.
| Age | 62 |
| Tenure | 11 years |
| Address | 12010 Sunset Hills Road, Reston, VA, United States, 20190 |
| Phone | 703 676 4300 |
| Web | https://www.saic.com |
Science Applications Management Efficiency
The company has return on total asset (ROA) of 0.0583 % which means that it generated a profit of $0.0583 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1672 %, meaning that it created $0.1672 on every $100 dollars invested by stockholders. Science Applications' management efficiency ratios could be used to measure how well Science Applications manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to 0.12. In addition to that, Return On Capital Employed is expected to decline to 0.10. At present, Science Applications' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 1.4 B, whereas Total Assets are forecasted to decline to about 4.7 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Kovarik | Leidos Holdings | 71 | |
| Debora Plunkett | CACI International | 60 | |
| Brian Callaghan | ASGN Inc | 49 | |
| David Wajsgras | Parsons Corp | 60 | |
| Karen Dykstra | Gartner | 61 | |
| William Wallace | CACI International | 73 | |
| William Jews | CACI International | 68 | |
| Frank Kendall | Leidos Holdings | 71 | |
| Mariel Joliet | ASGN Inc | 54 | |
| Surya Mohapatra | Leidos Holdings | 71 | |
| Noel Williams | Leidos Holdings | 65 | |
| William Grabe | Gartner | 81 | |
| Edwin Sheridan | ASGN Inc | 50 | |
| Richard Bressler | Gartner | 62 | |
| Stephen Pagliuca | Gartner | 65 | |
| Gareth Williams | WNS Holdings | 67 | |
| Miriam John | Leidos Holdings | 72 | |
| Mark Verdi | Genpact Limited | 54 | |
| David Fubini | Leidos Holdings | 67 | |
| Raul Cesan | Gartner | 72 | |
| Stacey Cartwright | Genpact Limited | 57 | |
Management Performance
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0583 |
Science Applications Leadership Team
Elected by the shareholders, the Science Applications' board of directors comprises two types of representatives: Science Applications inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Science. The board's role is to monitor Science Applications' management team and ensure that shareholders' interests are well served. Science Applications' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Science Applications' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dorothy Helfenstein, Executive Vice President Chief Strategic Growth Officer | ||
| Yvette Kanouff, Independent Director | ||
| Steven Mahon, Executive Vice President, General Counsel, Secretary | ||
| Donna Morea, Non-Executive Independent Chairman of the Board | ||
| Nathan Rogers, Chief Officer | ||
| Hilary Hageman, General VP | ||
| Joseph DeNardi, Senior Treasurer | ||
| John Bonsell, Senior Affairs | ||
| Prabu Natarajan, Chief Financial Officer, Executive Vice President | ||
| Garth Graham, Independent Director | ||
| Robert Genter, Executive Vice President and General Manager - Civilian Markets Group | ||
| Nazzic Keene, Sector President of Global Markets and Missions | ||
| Mark Escobar, Executive Operations | ||
| Robert Bedingfield, Independent Director | ||
| Steven Shane, Independent Director | ||
| Milford McGuirt, Director | ||
| Josh Jackson, Executive Unit | ||
| Hilary JD, General VP | ||
| Catherine HernandezBlades, Senior Communications | ||
| Michelle OHara, Chief Human Resource Officer, Executive Vice President | ||
| Paul Greiner, Senior Counsel | ||
| Michael LaRouche, Executive Vice President and General Manager - National Security Group | ||
| Toni TownesWhitley, CEO Director | ||
| Lucy Fitch, Chief VP | ||
| Maria Bishop, Senior Controls | ||
| Katharina McFarland, Independent Director | ||
| Carol Goode, Independent Director | ||
| John Hamre, Independent Director | ||
| Timothy Mayopoulos, Independent Director |
Science Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Science Applications a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0583 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 8.43 B | ||||
| Shares Outstanding | 49.52 M | ||||
| Shares Owned By Insiders | 0.96 % | ||||
| Shares Owned By Institutions | 77.36 % | ||||
| Number Of Shares Shorted | 683.9 K | ||||
| Price To Earning | 30.77 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Science Applications offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Science Applications' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Science Applications International Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Science Applications International Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Science Applications International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is IT Consulting & Other Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Science Applications. If investors know Science will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Science Applications listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.65) | Dividend Share 1.48 | Earnings Share 5.59 | Revenue Per Share 140.869 | Quarterly Revenue Growth 0.019 |
The market value of Science Applications is measured differently than its book value, which is the value of Science that is recorded on the company's balance sheet. Investors also form their own opinion of Science Applications' value that differs from its market value or its book value, called intrinsic value, which is Science Applications' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Science Applications' market value can be influenced by many factors that don't directly affect Science Applications' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Science Applications' value and its price as these two are different measures arrived at by different means. Investors typically determine if Science Applications is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Science Applications' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.